Alpha 2.0
Login Register
» Authors » Josephine M Norquist

Josephine M Norquist

Explore the profile of Josephine M Norquist including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 528
Followers 0
Related Specialties
Pharmacology
Public Health
Oncology
Top 10 Co-Authors
Ray Fitzpatrick
Crispin Jenkinson
Nancy C Santanello
Douglas J Watson
Eric Van Cutsem
Maria Alsina
Eray Goekkurt
Mayur Amonkar
John F Paolini
Kei Muro
Published In
Qual Life Res
Gastric Cancer
J Clin Epidemiol
Value Health
Health Qual Life Outcomes
Affiliations
Soon will be listed here.
Recent Articles
1.
Evaluation of the Content Validity of the COVID-19 Symptoms Daily Diary
Dine J, Guan Y, Milien M, Ervin C, Byrne D, Brown M, et al.
Patient Relat Outcome Meas . 2025 Jan; 16():37-53. PMID: 39839844
Introduction: The COVID-19 Symptoms Daily Diary (CSDD) is a patient-reported outcome measure designed to assess the severity of core COVID-19 symptoms in clinical trials. The preliminary version of the CSDD...
2.
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Qin S, Fang W, Ren Z, Ou S, Lim H, Zhang F, et al.
Liver Cancer . 2024 Aug; 13(4):389-400. PMID: 39114760
Introduction: KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular carcinoma. We...
3.
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
Mansoor W, Joo S, Norquist J, Kato K, Sun J, Shah M, et al.
Oncologist . 2024 May; 29(10):e1324-e1335. PMID: 38815152
Background: In the KEYNOTE-590 study, first-line pembrolizumab plus chemotherapy provided statistically significant improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy, with a manageable safety profile...
4.
Psychometric evaluation of the respiratory syncytial virus infection, intensity and impact questionnaire (RSV-iiiQ) in adults
Williams V, Romano C, Finelli L, Qin S, Saretsky T, Ma J, et al.
Health Qual Life Outcomes . 2024 Feb; 22(1):19. PMID: 38378572
Background: Despite a number of respiratory syncytial virus (RSV) vaccine candidates being tested in clinical trials, disease-specific, self-reported instruments assessing symptom severity of RSV infection from the perspective of adult...
5.
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey
Pinto C, Tervonen T, Jimenez-Moreno C, Levitan B, Soriano Gabarro M, Girman C, et al.
Patient . 2023 Dec; 17(2):147-159. PMID: 38085458
Objectives: To understand industry practices and challenges when submitting patient experience data (PED) for regulatory decisions by the US Food and Drug Administration (FDA). Methods: A two-part online survey related...
6.
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Guan Y, Puenpatom A, Johnson M, Zhang Y, Zhao Y, Surber J, et al.
Clin Infect Dis . 2023 Jul; 77(11):1521-1530. PMID: 37466374
Background: Molnupiravir is an orally administered antiviral authorized for COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report secondary and post hoc analyses of...
7.
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study
Maio M, Amonkar M, Norquist J, Ascierto P, Manzyuk L, Motola-Kuba D, et al.
Eur J Cancer . 2022 May; 169:188-197. PMID: 35588692
Background: In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair‒deficient (dMMR) non-colorectal solid...
8.
Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): Measurement Properties and Estimated Clinically Meaningful Thresholds From a Phase 3 Study
Williams P, Burke T, Norquist J, Daskalopoulou C, Speck R, Samkari A, et al.
JTO Clin Res Rep . 2022 Apr; 3(4):100298. PMID: 35400081
Introduction: The NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ) was developed to assess NSCLC symptom severity in accordance with Food and Drug Administration evidentiary expectations leading to Food and Drug Administration qualification...
9.
Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial
Butler J, Spertus J, Bamber L, Khan M, Roessig L, Vlajnic V, et al.
Eur J Heart Fail . 2022 Mar; 24(5):843-850. PMID: 35274420
Aims: Clinically important thresholds in patient-reported outcomes measures like the Kansas City Cardiomyopathy Questionnaire (KCCQ) have not been defined for patients with heart failure and preserved ejection fraction (HFpEF). The...
10.
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Van Cutsem E, Amonkar M, Fuchs C, Alsina M, Ozguroglu M, Bang Y, et al.
Gastric Cancer . 2021 Sep; 24(6):1341. PMID: 34536168
No abstract available.